share_log

Ladenburg Thalmann Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $2

Benzinga Real-time News ·  Aug 3, 2022 07:10

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment